Johnson & Johnson (JNJ) is DnB Asset Management AS’s 6th Largest Position
DnB Asset Management AS raised its position in Johnson & Johnson (NYSE:JNJ) by 1.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,305,025 shares of the company’s stock after buying an additional 15,600 shares during the period. Johnson & Johnson comprises about 2.6% of DnB Asset Management AS’s holdings, making the stock its 6th largest position. DnB Asset Management AS’s holdings in Johnson & Johnson were worth $162,541,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. Cleararc Capital Inc. raised its position in shares of Johnson & Johnson by 1.1% in the fourth quarter. Cleararc Capital Inc. now owns 74,290 shares of the company’s stock valued at $8,559,000 after buying an additional 825 shares in the last quarter. Artisan Partners Limited Partnership raised its position in shares of Johnson & Johnson by 3.7% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,554,500 shares of the company’s stock valued at $409,514,000 after buying an additional 127,662 shares in the last quarter. Elgethun Capital Management purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $2,801,000. CLS Investments LLC raised its position in shares of Johnson & Johnson by 3.1% in the fourth quarter. CLS Investments LLC now owns 3,308 shares of the company’s stock valued at $381,000 after buying an additional 98 shares in the last quarter. Finally, Turner Investments LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $218,000. Hedge funds and other institutional investors own 66.01% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.29% on Friday, hitting $132.96. The stock had a trading volume of 2,138,325 shares. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The company has a 50 day moving average of $133.33 and a 200-day moving average of $125.48. The firm has a market capitalization of $358.17 billion, a P/E ratio of 22.50 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.83%. The firm had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same quarter last year, the business posted $1.74 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be given a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/04/johnson-johnson-jnj-shares-bought-by-dnb-asset-management-as-updated-updated-updated.html.
Several brokerages recently issued reports on JNJ. BTIG Research lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target on the stock. in a research note on Friday, July 21st. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target on the stock. in a research note on Friday, July 21st. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Finally, Credit Suisse Group started coverage on Johnson & Johnson in a research note on Thursday, July 20th. They set an “outperform” rating and a $148.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $133.72.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.